Late season interim estimates of influenza vaccine effectiveness reliably predict end of season estimates in Victoria, Australia, 2007 to 2012

Eurosurveillance

Volumn 18, Issue 41, 2013, Pages

  Sullivan, S G ^a   Kelly, H ^b,c  

^a WHO COLLABORATING CENTRE FOR REFERENCE AND RESEARCH ON INFLUENZA   (Australia)

^b VICTORIAN INFECTIOUS DISEASES REFERENCE LABORATORY   (Australia)

^c AUSTRALIAN NATIONAL UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE;

AUSTRALIA; GENETICS; HUMAN; IMMUNOLOGY; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; INFLUENZA VIRUS B; INFLUENZA, HUMAN; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEASON; SENTINEL SURVEILLANCE; SOCIOECONOMICS; STATISTICAL MODEL; VERY ELDERLY;

AGED, 80 AND OVER; AUSTRALIA; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA B VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; LOGISTIC MODELS; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SEASONS; SENTINEL SURVEILLANCE; SOCIOECONOMIC FACTORS; VICTORIA;

EID: 84885593115     PISSN: 1025496X     EISSN: 15607917     Source Type: Journal    
DOI: 10.2807/1560-7917.ES2013.18.41.20605     Document Type: Article

References (30)

1. Barr IG, McCauley J, Cox N, Daniels R, Engelhardt OG, Fukuda K, et al. Epidemiological, antigenic and genetic characteristics of seasonal influenza A(H1N1), A(H3N2) and B influenza viruses: basis for the WHO recommendation on the composition of influenza vaccines for use in the 2009-2010 Northern Hemisphere season. Vaccine. 2009;28(5):1156-67. http://dx.doi.org/10.1016/j.vaccine.2009.11.043. PMid:20004635.
2. World Health Organization (WHO). WHO recommendations on the composition of influenza virus vaccines. Geneva: WHO. [Accessed 23 Sep 2013]; Available from:http://www.who.int/influenza/vaccines/virus/recommendations/en/
3. Valenciano M, Kissling E, I-MOVE case-control study team. Early estimates of seasonal influenza vaccine effectiveness in Europe: results from the I-MOVE multicentre case-control study, 2012/13. Euro Surveill. 2013;18(7):pii=20400. Available from: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20400
4. Skowronski DM, Janjua NZ, De Serres G, Dickinson JA, Winter A, Mahmud SM, et al. Interim estimates of influenza vaccine effectiveness in 2012/13 from Canada's sentinel surveillance network, January 2013. Euro Surveill. 2013;18(5):pii=20394. Available from: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20394
5. McMenamin J, Andrews N, Robertson C, Fleming DM, Durnall H, von Wissmann B, et al. Effectiveness of seasonal 2012/13 vaccine in preventing laboratory-confirmed influenza infection in primary care in the United Kingdom: mid-season analysis 2012/13. Euro Surveill. 2013;18(5):pii=20393. Available from:http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20393
6. Centers for Disease Control and Prevention (CDC). Interim adjusted estimates of seasonal influenza vaccine effectiveness-United States, February 2013. MMWR Morb Mortal Wkly Rep. 2013;62(7):119-23. PMid:23425960.
7. Castilla J, Martínez-Baz I, Martínez-Artola V, Fernandez-Alonso M, Reina G, Guevara M, et al. Early estimates of influenza vaccine effectiveness in Navarre, Spain: 2012/13 mid-season analysis. Euro Surveill. 2013;18(7):pii=20404. Available from: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20404
8. Bragstad K, Emborg HD, Fischer TK, Voldstedlund M, Gubbels S, Andersen B, et al. Low vaccine effectiveness against influenza A(H3N2) virus among elderly people in Denmark in 2012/13-a rapid epidemiological and virological assessment. Euro Surveill. 2013;18(6):pii=20397. Available from:http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20397
9. Centers for Disease Control and Prevention (CDC). Early estimates of seasonal influenza vaccine effectiveness--United States, January 2013. MMWR Morb Mortal Wkly Rep. 2013;62(2):32-5. PMid:23325354.
10. Kissling E, Valenciano M, I-MOVE case-control studies team. Early estimates of seasonal influenza vaccine effectiveness in Europe, 2010/11: I-MOVE, a multicentre case-control study. Euro Surveill. 2011;16(11):pii=19818. Available from: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19818. PMid:21435329.
11. Kissling E, Valenciano M, Cohen JM, Oroszi B, Barret AS, Rizzo C, et al. I-MOVE multi-centre case control study 2010-11: overall and stratified estimates of influenza vaccine effectiveness in Europe. PLoS One. 2011;6(11):e27622. http://dx.doi.org/10.1371/journal.pone.0027622. PMid:22110695. PMCid:PMC3216983.
12. Kissling E, Valenciano M, Larrauri A, Oroszi B, Cohen JM, Nunes B, et al. Low and decreasing vaccine effectiveness against influenza A(H3) in 2011/12 among vaccination target groups in Europe: results from the I-MOVE multicentre case-control study. Euro Surveill. 2013;18(5):pii=20390. Available from:http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20390
13. Pebody RG, Andrews N, McMenamin J, Durnall H, Ellis J, Thompson CI, et al. Vaccine effectiveness of 2011/12 trivalent seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: evidence of waning intra-seasonal protection. Euro Surveill. 2013;18(5):pii=20389. Available from:http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20389
14. Castilla J, Martínez-Baz I, Martínez-Artola V, Reina G, Pozo F, García Cenoz M, et al. Decline in influenza vaccine effectiveness with time after vaccination, Navarre, Spain, season 2011/12. Euro Surveill. 2013;18(5):pii=20388. Available from: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20388
15. Belongia EA, Kieke BA, Donahue JG, Coleman LA, Irving SA, Meece JK, et al. Influenza vaccine effectiveness in Wisconsin during the 2007-08 season: comparison of interim and final results. Vaccine. 2011;29(38):6558-63. http://dx.doi.org/10.1016/j.vaccine.2011.07.002. PMid:21767593.
16. Kelly H, Carville K, Grant K, Jacoby P, Tran T, Barr I. Estimation of influenza vaccine effectiveness from routine surveillance data. PLoS One. 2009;4(3):e5079. http://dx.doi.org/10.1371/journal.pone.0005079. PMid:19333374. PMCid:PMC2658741.
17. Foppa IM, Haber M, Ferdinands JM, Shay DK. The case test-negative design for studies of the effectiveness of influenza vaccine. Vaccine. 2013;31(30):3104-9. http://dx.doi.org/10.1016/j.vaccine.2013.04.026. PMid:23624093.
18. Jackson ML, Nelson JC. The test-negative design for estimating influenza vaccine effectiveness. Vaccine. 2013;31(17):2165-8. http://dx.doi.org/10.1016/j.vaccine.2013.02.053. PMid:23499601.
19. Orenstein EW, De Serres G, Haber MJ, Shay DK, Bridges CB, Gargiullo P, et al. Methodologic i-ssues regarding the use of three observational study designs to assess influenza vaccine effectiveness. Int J Epidemiol. 2007;36(3):623-31. http://dx.doi.org/10.1093/ije/dym021. PMid:17403908.
20. Thursky K, Cordova SP, Smith D, Kelly H. Working towards a simple case definition for influenza surveillance. J Clin Virol. 2003;27(2):170-9. http://dx.doi.org/10.1016/S1386-6532(02)00172-5. PMid: 12829039.
21. Fielding JE, Grant KA, Tran T, Kelly HA. Moderate influenza vaccine effectiveness in Victoria, Australia, 2011. Euro Surveill. 2012;17(11):pii=20115. Available from: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20115. PMid:22449867.
22. Fielding JE, Grant KA, Garcia K, Kelly HA. Effectiveness of seasonal influenza vaccine against pandemic (H1N1) 2009 virus, Australia, 2010. Emerg Infect Dis. 2011;17(7):1181-7. http://dx.doi.org/10.3201/eid1707.101959. PMid:21762570. PMCid:PMC3381383.
23. Fielding JE, Grant KA, Papadakis G, Kelly HA. Estimation of type-and subtype-specific influenza vaccine effectiveness in Victoria, Australia using a test negative case control method, 2007-2008. BMC Infect Dis. 2011;11:170. http://dx.doi.org/10.1186/1471-2334-11-170. PMid:21669006. PMCid:PMC3131256.
24. Kelly HA, Grant KA, Fielding JE, Carville KS, Looker CO, Tran T, et al. Pandemic influenza H1N1 2009 infection in Victoria, Australia: No evidence for harm or benefit following receipt of seasonal influenza vaccine in 2009. Vaccine. 2011;29(37):6419-26. http://dx.doi.org/10.1016/j.vaccine.2011.03.055. PMid:21473950.
25. Sullivan SG, Tay EL, Kelly H. Variable definitions of the influenza season and their impact on vaccine effectiveness estimates. Vaccine. 2013;31(40):4280-3. http://dx.doi.org/10.1016/j.vaccine.2013.06.103. PMid:23850417.
26. Kelly H, Grant K. Interim analysis of pandemic influenza (H1N1) 2009 in Australia: surveillance trends, age of infection and effectiveness of seasonal vaccination. Euro Surveill. 2009;14(31):pii=19288. Available from:http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19288
27. Kissling E, Valenciano M, I-MOVE case-control studies team. Early estimates of seasonal influenza vaccine effectiveness in Europe among target groups for vaccination: results from the I-MOVE multicentre case-control study, 2011/12. Euro Surveill. 2012;17(15):pii=20146. Available from:http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20146. PMid:22516046.
28. Greenland S, Lash TL. Bias Analysis. In: Rothman KJ, Greenland S, Lash TL, eds. Modern Epidemiology. 3rd ed. Philadelphia: Lippincott, Williams & Wilkins, 2008:345-80.
29. Heinze G, Schemper M. A solution to the problem of separation in logistic regression. Stat Med. 2002;21(16):2409-19. http://dx.doi.org/10.1002/sim.1047. PMid:12210625.
30. Skowronski DM, De Serres G, Dickinson J, Petric M, Mak A, Fonseca K, et al. Component-specific effectiveness of trivalent influenza vaccine as monitored through a sentinel surveillance network in Canada, 2006-2007. J Infect Dis. 2009;199(2):168-79. http://dx.doi.org/10.1086/595862. PMid:19086914.